A recent study found nearly one in six children started on these medications received a diagnosis of a nutritional deficiency within a year, with vitamin D problems being the most common. For kids and teens, even modest shortfalls in vitamins and minerals can affect bone growth, immune function, energy, and learning. Families and clinicians need clear plans for monitoring and preventing deficits while pursuing metabolic and weight-related goals.
Understanding these trade-offs matters for building equitable care that supports long-term growth and opportunity. If you’re caring for a child on or considering GLP-1 therapy, look for guidance about screening, supplements, and diet adjustments from trusted clinicians. Follow the link to see how researchers measured this risk and what that might mean for supporting healthier development and inclusion for all young people.
Children taking GLP-1 medications (such as Victoza, Saxenda, Trulicity, and Ozempic) for weight loss, prediabetes, or type 2 diabetes may face an overlooked risk: nutritional deficiencies. A new study found that nearly 1 in 6 young patients developed a diagnosed deficiency within a year of starting treatment, with vitamin D deficiency affecting about 12%.
